TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Oric Pharmaceuticals
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

ORIC Pharmaceuticals presented promising Phase 1b trial results for enozertinib, demonstrating strong systemic and CNS activity in NSCLC patients with EGFR exon 20 mutations, with high objective response rates and a competitive safety profile.

Insights
AKRO   neutral

Being acquired by Novo Nordisk with cash payment and contingent value right


ORIC   positive

Presented strong preliminary clinical trial data showing high objective response rates (67% in 1L, 45% in 2L), 100% intracranial response in some patient groups, manageable safety profile, and potential best-in-class positioning for their drug enozertinib